Study of Intradermal Injections of RCS-01 in Male and Female Subjects

Skin Wrinkling Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02391935
• Other study ID #: RCS-01-001-2014
• Status: Completed
• Phase: Phase 1
• First received: March 12, 2015
• Last updated: October 10, 2017
• Start date: October 10, 2015
• Est. completion date: July 12, 2017

Study information

• Verified date: October 2017
• Source: RepliCel Life Sciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to assess the safety profile of RCS-01 injections as compared to placebo injections. This study will also measure the impact these injections will have on skin markers related to aging through evaluation of gene expression profiles.

30 participants will be selected for this study based on their health status, current/past medications, and ability to adhere to protocol-related requirements. At the first visit and after providing informed consent, participants are evaluated against the study inclusion/exclusion criteria and provide blood samples for screening assessments (including virology). If suitable for study participation, participants will provide a biopsy from the scalp from which RCS-01 will be prepared and will have four treatment evaluation sites identified on their buttocks, two on each side.

Study participants will be randomized to one of two treatment subgroups. Participants in the RCS-01 Subgroup (n=24) will receive injections of RCS-01 or placebo or a 'sham' injection (a needle penetration without injection of liquid). Participants in the the Placebo Subgroup (n= 6) will be randomized to receive only injections of placebo or sham injections.

Baseline evaluations of subjects' overall health and skin condition at treatment sites on their buttocks will be performed before receipt of injections at Day 0. In addition to injections delivered at Day 0, the pre-selected treatment evaluation sites will receive intradermal injections of RCS-01 or placebo (cryomedium) or a sham injection four (4) and eight (8) weeks after Day 0 according to a randomization schedule for a total of three (3) injections per treatment site.

All participants will return to the clinic for at least 9 visits during the 52-week follow-up period to monitor long-term safety. At the 12-week time point, 18 randomly-selected participants from the RCS-01 Subgroup will provide biopsies from all injection sites for analysis of skin markers related to aging. At the 26-week time point, the remaining participants will provide biopsies of all injection sites for histopathological analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: July 12, 2017
• Est. primary completion date: July 12, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female Caucasian in good health between the age of 50 and 65 years.

2. Female subjects must be post-menopausal for at least one year or surgically sterile.

3. Signed and dated informed consent and willingness to attend all study visits and complete all procedures required by this protocol.

4. The treatment evaluation sites are of uniform skin color without erythema, dark pigmentation or scars that may confound study results.

Exclusion Criteria:

1. Any transient skin disorder or infections (e.g. pyoderma, tinea corporis, contact or irritative dermatitis, scleroderma etc.) within 20 cm of the treatment evaluation sites or the presence of tattoos near the treatment sites.

2. Subjects diagnosed with psoriasis, lichen planus, vitiligo, systemic scleroderma, or lupus erythematosus.

3. Any condition that, in the investigator's opinion, would impact subject's safety and/or a subject's ability to complete all study related procedures.

4. History of infection with or positive serology results for human immunodeficiency virus (HIV), hepatitis B or C, or syphilis.

5. Presence/history of hypertrophic scars and/or keloids.

6. Subjects diagnosed with cancer with or without chemotherapy treatment within 3 years prior enrollment.

7. Women who are pregnant or nursing.

8. Current use of any medications not permitted in the study

9. Ongoing or recent participation in a cosmetic and/or clinical research study prior to enrolment.

10. Subject not agreeing to avoid UV exposure (sun, solarium) on the nude buttocks during the study period.

11. Known allergy or hypersensitivity to human serum albumin, DMSO, gentamicin, material of bovine origin and/or local anesthetics.

12. Close affiliation with the investigational site (e.g., a close relative of the investigator or a possibly dependent person (e.g., employee or student of the investigational site)).

13. Subjects diagnosed with coagulopathies or significant thrombocytopenia

Related Conditions & MeSH terms

• Intrinsic Aging of Skin
• Skin Wrinkling
• Solar Degeneration of Skin

Intervention

Drug:
• RCS-01
Cultured, autologous hair follicle cells suspended in cryomedium
• Placebo
Cryomedium

Device:
• Sham injection
skin penetration of the needle without injection of liquid

Locations

Country	Name	City	State
Germany	IUF Leibniz-Institut für umweltmedizinische Forschung gGmbH	Düsseldorf

Sponsors (6)

Lead Sponsor	Collaborator
RepliCel Life Sciences, Inc.	Datinf GmbH, Innovacell Biotechnologie AG, JensonR+ Limited, PHARMALOG Institut für klinische Forschung GmbH, Syreon Corporation

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of local adverse events	Within-patient comparison of the local (reported at treatment evaluation sites) adverse event profile between treatment evaluation sites treated with RCS-01 or placebo. The local adverse event profile is defined by the incidence, relationship to treatment, severity and seriousness of adverse events reported at the treatment evaluation sites.	52 weeks after first injection
Secondary	Incidence of adverse events	Between-subject comparison of the systemic (not reported at treatment evaluation sites) adverse event profile between participants in the RCS-01 Subgroup versus Placebo Subgroup.	52 weeks after first injection
Secondary	Incidence of abnormalities in skin structure	A within-patient and between patient comparison of histology results from analyses performed on biopsies obtained from treatment evaluation sites.	52 weeks after first injection
Secondary	Incidence of changes in markers related to skin aging	Markers to be assessed include fibrillar collagen type I (COL 1A1, COL 1A2) and type III (COL 3A1), transforming growth factor beta1, connective tissue growth factor, matrix metalloproteinases 1, 3 and 9, tissue inhibitor of matrix metalloproteinase 1 and lumican . Incidence of changes within- and between-participants.	12 weeks after first injection

External Links

•   RepliCel Life Sciences, Inc. Website